...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith down 50% this morning in US

,,yes,,down,,cuz,,,,,,aren't we 8 years ahead of others in epigenetic research,,,,thats why others in our field are seeing buyouts,,,,,, :o) ,,,,,,its so pitiful it actually hits a funny bone!

Share
New Message
Please login to post a reply